https://scholars.lib.ntu.edu.tw/handle/123456789/545090
標題: | Morphine for dyspnea control in terminal cancer patients: Is it appropriate in Taiwan? | 作者: | WEN-YU HU TAI-YUAN CHIU SHAO-YI CHENG Chen C.-Y. |
公開日期: | 2004 | 卷: | 28 | 期: | 4 | 起(迄)頁: | 356-363 | 來源出版物: | Journal of Pain and Symptom Management | 摘要: | Morphine for dyspnea control usually arouses ethical controversy in terminal cancer care. This study prospectively assessed the use of morphine for dyspnea control in terminal cancer patients in terms of two characteristics: the extent to which medical staff, family, and patients found morphine to be ethically acceptable and efficacious, and the influence of morphine on survival. One hundred and thirty-six palliative care patients meeting specific eligibility criteria were enrolled. A structured data collection form was used daily to evaluate clinical conditions, which were analyzed at the time of admission and 48 h before death. Sixty-six (48.6%) of the 136 patients had dyspnea on admission. The intensity was mild in 14.0% and moderate or severe in 34.6%. The intensity of dyspnea became worse 48 h before death (4.29±2.55 vs. 4.94±2.60, P<0.001, range 0-10). Twenty-seven (40.9%) of 66 patients with dyspnea received morphine on admission for the control of dyspnea; the routes of administration were oral (59.3%) and subcutaneous (40.7%). Fewer than two-thirds (59.3%) of the patients were given morphine with the consent of both patient and family. More than one-third (40.7%) on admission and about one-half (52.8%) in the 48 h before death had the consent of family alone. Positive ethical acceptability and satisfaction with using morphine for dyspnea control were found in both medical staff and family in this study. Multiple Cox regression analysis showed that using morphine for dyspnea, both on admission and in the 48 h before death, did not significantly influence the patients' survival (HR: 0.015, 95% CI: 0.00-4.23; HR: 1.76, 95% CI: 0.73-4.24). In this population, the use of morphine for dyspnea control in the terminal phase of cancer was effective and ethically validated in the study. Research efforts to find the most appropriate route and dosage of morphine for dyspnea, based on the patient's situation, remain worthwhile. ? 2004 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-4744358082&doi=10.1016%2fj.jpainsymman.2004.01.004&partnerID=40&md5=8389c2383ee5806e55dd7452277ffa58 https://scholars.lib.ntu.edu.tw/handle/123456789/545090 |
ISSN: | 0885-3924 | DOI: | 10.1016/j.jpainsymman.2004.01.004 | SDG/關鍵字: | morphine; adolescent; adult; aged; article; cancer; cancer patient; cancer staging; cancer survival; controlled study; death; disease control; disease severity; drug efficacy; dyspnea; family; female; hospital admission; human; informed consent; major clinical study; male; medical staff; multiple regression; palliative therapy; patient satisfaction; statistical analysis; statistical significance; Taiwan; Adolescent; Adult; Aged; Analgesics, Opioid; Attitude of Health Personnel; Dyspnea; Female; Humans; Male; Middle Aged; Morphine; Neoplasms; Palliative Care; Patient Satisfaction; Risk Assessment; Risk Factors; Taiwan; Terminal Care; Treatment Outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。